New Delhi, April 4 (NationPress) – India's drug regulatory authorities are enhancing their vigilance over the rapidly evolving landscape of weight-loss and diabetes treatments, specifically focusing on GLP-1 receptor agonists. This comes in response to escalating demand and the expected influx of more affordable generic options into the local market.

The Indian Pharmacopoeia Commission (IPC), operating under the Ministry of Health, has been assigned the critical role of systematically gathering and evaluating reports of adverse events associated with these medications.

This initiative is designed to bolster post-marketing surveillance, ensuring any safety issues are promptly detected and resolved.

Officials revealed that this action is part of a larger regulatory strategy to keep pace with the swift adoption of these therapies, particularly as they become more affordable.

Following the patent expiration of semaglutide, a vital component in sought-after weight-loss solutions, the market is poised for an influx of budget-friendly generic alternatives. While this may broaden access, it also heightens the risk of misuse.

The intensified monitoring is a continuation of recent enforcement efforts spearheaded by the Drug Controller General of India (DCGI), which has ramped up inspections to combat the unauthorized sale and promotion of GLP-1 medications.

In recent weeks, authorities have audited 49 establishments nationwide, including online pharmacy warehouses, wholesalers, retailers, and weight-loss clinics.

These inspections were carried out in various regions and aimed to uncover violations such as sales without prescriptions, improper prescribing practices, and deceptive marketing tactics.

Violators have received notices, with the government cautioning that persistent non-compliance could result in license revocations, financial penalties, and legal repercussions.

The Centre has also clarified that only certified specialists, including endocrinologists, internal medicine professionals, and cardiologists, are permitted to prescribe these medications.

Earlier, on March 10, the government instructed manufacturers to cease misleading advertisements and any promotions that might encourage unsupervised usage.

GLP-1 receptor agonists, prevalent in managing type 2 diabetes and increasingly prescribed for weight loss, function by stimulating insulin production and curbing appetite through delayed gastric emptying.

However, health officials have flagged potential side effects, which can range from nausea and vomiting to more severe concerns such as pancreatitis, kidney damage, and bowel obstruction.